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Abstract 
Background: The BCR/ABL tyrosine kinase inhibitor imatinib is highly effective in the 
treatment of chronic myeloid leukemia (CML) but fails to eliminate all leukemia cells. In 
this study, we investigated whether the addition of granulocyte colony-stimulating 
factor (G-CSF) could reduce the level of residual disease in patients with Ph-positive CML 
who appeared to have achieved a suboptimal response to imatinib alone.  
Methods: Eleven patients with CML who had achieved ≥35% Ph-negativity on imatinib 
were enrolled. The starting dose of imatinib was 400 mg or 600 mg orally daily, and of G-
CSF 5 μg/kg s.c. daily. The administration of G-CSF was postponed or interrupted in the 
event of leukocytosis (≥30 ×109 leukocytes/l) until the white blood cell count fell below 
20 × 109/l. Efficacy was assessed by serial monitoring of blood levels of BCR-ABL 
transcripts.  
Results: Of 11 evaluable patients, 9 had an appreciable decline in BCR-ABL transcript 
levels; in 7 cases the reduction was greater than 1 log.  
Conclusions: We conclude that the addition of G-CSF should be considered for patients 
on imatinib who fail to obtain optimal response to imatinib alone and that this approach 
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Chronic myeloid leukemia (CML) is a clonal disease of hemopoietic
 stem cell origin 
characterized by the t(9;22) chromosomal translocation
 that generates the BCR/ABL 
oncogene [1, 2]. Imatinib (Gleevec or Glivec; Novartis Pharmaceuticals, Basel, 
Switzerland), a small-molecule inhibitor of the BCR/ABL
 tyrosine kinase, has proven to 
be highly effective for the treatment
 of CML. Imatinib induces rapid hematologic and 
complete cytogenetic responses (CCRs) in most chronic-phase CML patients (82% at 30 
months) but rarely eradicates the BCR-ABL
+ clone [3–5]. The persistence in most 
imatinib-treated patients of a small but molecularly detectable
 population of leukemic 
cells is of concern as they represent
 a potential reservoir from which mutant imatinib-
resistant
 CML cells may emerge [6]. Moreover, it is likely that the treatment of patients 
with imatinib is less effective on the most primitive, quiescent leukemic cells that display 
stem cell properties, as experienced in immunodeficient mice [7]. In vitro studies have 
further
 shown that imatinib exerts an antiproliferative effect
 on these primitive quiescent 
CML cells that reduces their rate
 of elimination [8, 9]. 
Recently, in vitro studies have shown that
 intermittent exposure to granulocyte colony-
stimulating factor (G-CSF) can enhance the effect
 of imatinib on CML cells by specifically 
targeting
 the primitive quiescent leukemic elements [10, 11]. 
Taken together, these observations prompted us to look for a
 treatment that might 
enhance the rate of entry into the cycle of
 primitive quiescent CML cells and thereby 
improve responsiveness
 to imatinib. For these reasons, a pilot study was designed to 
involve the addition of G-CSF to imatinib for patients with CML who had achieved a 
partial cytogenetic response or a CCR with an apparent plateau of BCR-ABL transcript 
numbers at suboptimal levels. These patients were classified as partially sensitive to 
imatinib such that they might benefit from the addition of growth factor stimulation. 
Patients and Methods 
Patients 
A total of 11 patients were registered in this study between January 2005 and March 2008 (table 1). 
Patients were eligible if they met all the following criteria: (1) treatment with imatinib at a minimum 
dose of 400 mg per day for at least 2 years; (2) the achievement of at least a minor cytogenetic response 
(defined as at least 35% of Ph-negative marrow metaphases); (3) achievement of a plateau in BCR-ABL 
transcripts defined by measuring BCR-ABL transcripts on at least 4 occasions over a minimum period 
of 1 year, with the latest value not lower than the previous minimum value. Patients were excluded from 
the study if their imatinib dosage had been modified over the preceding 12 months. Other eligibility 
criteria included age ≥18 years, bilirubin <1.5 × upper limit
 of normal value, serum creatinine <2.0 
mg/dl, aspartate aminotransferase
 <3.0 × upper limit of normal value, left ventricular ejection
 fraction 
>40%, and a prediction of pulmonary function forced expiratory
 volume at 1s >50%. Pregnancy and 
active
 infection were exclusion criteria. All patients gave signed informed consent indicating that they 
were aware of the investigational nature of this study, and the protocol was approved by the 
Institutional Review Board at Henan Tumor Hospital. The definitions of chronic and accelerated phases 
of CML, the classification of cytogenetic responses, and criteria for failure of interferon-α were based on 
previous publications [4, 12].  
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For these registered patients, the starting dose of imatinib was 400 or 600 mg orally daily, and of G-
CSF 5 μg/kg s.c. daily. The administration of G-CSF was postponed or interrupted in the event of 
leukocytosis (≥30 ×10
9 leukocytes/l) until the white blood cell count fell below 20 × 10
9/l. Treatment 
with G-CSF was discontinued if a patient did not achieve a reduction in the transcript level of at least 0.5 
log after 6 months. For patients whose BCR-ABL transcript levels continued to decline but who had not 
yet reached molecular remission, treatment was designed to continue for 1–6 months. The management 
of tumor lysis syndrome was performed under the guidelines of our institute.  
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction 
The numbers of BCR-ABL transcripts in the peripheral blood were measured serially while imatinib 
was administered as a single agent, at the time of starting G-CSF, and serially thereafter as Cross et al.
 
described [13]. Expression of the ABL gene was used as control and results were expressed as the BCR-
ABL/ABL ratio percentage. Occasional blood specimens were invalidated for technical reasons; for 
example, samples with control <1 ×10
4 ABL transcripts were considered suboptimal and were excluded 
from the analysis. In cases where BCR-ABL transcripts were undetectable by quantitative real-time 




Patients’ responses are shown in table 1. After G-CSF was added, the transcript levels 
declined by >0.5 log in 9 cases and by >1 log in 7 cases. The 5 patients not in CCR prior to 
G-CSF therapy achieved CCR (patients 1, 3, 5, 7 and 8). Patients 5 and 8 had developed a 
trisomy 8 in addition to the Ph chromosome in all metaphases when they were receiving 
interferon. Before enrollment in the study, they had been treated with imatinib, first 400 
mg and then 600 mg for 19 and 21 months, respectively, but failed to gain a major 
cytogenetic response. On G-CSF, both achieved a CCR; their marrow metaphases 
contained neither Ph chromosome nor trisomy 8. Two patients achieved complete 
molecular responses (patients 2 and 9). These molecular responses lasted for 7 months 
(patient 2) and 5 months (patient 9), respectively, after discontinuation of the G-CSF; 
transcript numbers had, by then, risen to levels similar to their respective baseline levels. 
Toxicity 
The most frequent grade 1–2 nonhematologic toxicities experienced in the study were 
nausea (n = 6) and fatigue (n = 8). In the majority of cases, these side effects were mild 
and did not prevent the administration of G-CSF. Grade 3–4 nonhematologic side effects 
consisted of myalgias (n = 1) and fatigue (n = 2). All patients had reactions at the site of 
injection (grade I), which needed 4–8 days to resolve. No bleeding episodes occurred. No 
patient discontinued therapy because of toxicity and there were no treatment-related 
deaths.  
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Imatinib treatment results in a significant inhibition of CML
 progenitor cell 
proliferation but only a modest increase in
 apoptosis [8, 9, 14]. Apoptosis is restricted to 
dividing cells,
 whereas nondividing cells resist apoptosis [8, 14]. Imatinib-induced
 
inhibition of CML progenitor proliferation together with the
 resistance of nondividing 
CML progenitors to imatinib-mediated
 apoptosis likely contributes to incomplete 
elimination of malignant
 progenitor cells in patients otherwise responding well to this
 
agent. Undivided CML progenitors remaining after imatinib treatment
 represent either 
dormant, noncycling cells, or cells that are
 inhibited from entering the cell cycle by the 
antiproliferative
 effects of imatinib. The antiproliferative effect of imatinib
 enhances this 
population of nondividing cells and potentially
 interferes with the elimination of 
malignant progenitors through apoptosis.
 Holtz et al. [14] have shown that the undivided 
population is BCR/ABL positive,
 is not enriched for BCR/ABL-negative cells, and 
expresses the
 BCR/ABL gene. In addition, the nondividing CML CD34
+ cell fraction is
 
also resistant to elimination following treatment with several
 therapeutic agents. 
Recently, in vitro studies have shown that G-CSF stimulation could activate CML 
progenitors into cell cycle and reduce the number of viable undivided CML progenitors 
that persist after imatinib treatment [10, 11]. In addition,
 G-CSF has been safely and 
successfully used for peripheral blood
 stem cell mobilization in healthy donors and in 
CML patients
 treated with imatinib with no significant increase
 in BCR-ABL transcript 
levels by quantitative reverse transcription-PCR [15, 16]. G-CSF is currently being used in 
patients with CML to overcome imatinib-induced neutropenia, as myelosuppression
 
during imatinib therapy has been found to be associated
 with a poorer cytogenetic 
response [17, 18]. In this setting,
 it has been postulated that the improved cytogenetic 
responses
 observed result from an increased exposure to imatinib [19–21]. However, 
another effect of pharmacologic doses
 of G-CSF given to CML patients might be to 
stimulate the entry
 of their quiescent CML stem cells into cycle and, hence, to increase
 the 
sensitivity of these cells to imatinib [10, 21, 22]. 
Recently, we demonstrated the existence of a population of rare, primitive cells with 
full characteristics of leukemic stem cells in bone marrow of CML patients [23], and 
further studies suggested that the G-CSF could significantly enhance the effect of imatinib 
on CML cells by specifically targeting these primitive quiescent leukemic elements in vitro 
[unpublished observations]. 
Conclusion 
The results of the current study provide a strong rationale for further clinical 
evaluation of the effectiveness of G-GSF in reducing residual disease in CML patients 
treated with imatinib. We suggest that the addition of G-CSF should be considered for 
patients on imatinib who fail to obtain optimal response to imatinib alone and that this 
approach deserves further evaluation as a frontline therapy for newly diagnosed CML. 
However, the mechanism of partial sensitivity to imatinib was not evaluated in this study. 
This could be an important factor in determining which
 patients might respond to the 
addition of G-CSF, and this should be addressed in future studies.  
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Clinical status at the 
onset of imatinib  
Dose of imatinib 
before G-CSF 
(mg/day)  
Time from onset 
of imatinib to G-
CSF therapy (m) 
 Baseline  
 Q-PCR before  
 G-CSF therapy  
Minimal  
Q-PCR before  
G-CSF therapy  
Q-PCR on  
G-CSF 6 m 
later  
>Log reduction from 
>baseline on G-CSF  
>6 m later  
01  39 (F)  newly diagnosed  400  32.4   17.2  04.8 0.58  >1 
02*  19 (M)  IFN-α failure  400  27.6  0 0.16  00.09 0  >1 
03  27 (F)  IFN-α failure  400  28.2   16.2  04.3 0.6  >1 
04  41 (M)  IFN-α failure  400  31  0 8.98  02.56  3.75  <0.5 lack of efficacy  
05  39 (F)  IFN-α failure  600  25.4   27  12.8  0.8  >1 
06  52 (M)  IFN-α failure  400  42.6  0 0.42  00.19 0.087  >0.5 
07  32 (M)  AP   600  27   26.5  11.8  0.56  >1 
08  19 (M)  IFN-α failure  600  27.2   25.1  15.4  0.52  >1 
09*  30 (M)  IFN-α failure  400  28  0 0.03  00.02 0  >1 
10  26 (F)  IFN-α failure  400  26.5  0 4.5  03.2  3.8  <0.5 lack of efficacy  
11  38 (M)  newly diagnosed  400  38.3  0 4.6   02.18 1.2  >0.5 
* Patients who achieved complete molecular responses on G-CSF 6 months later. IFN-α = Interferon-alpha; AP = accelerated 
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